BACKGROUND: In 2001, the Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments (CANMAT) partnered to produce evidence-based clinical guidelines for the treatment of depressive disorders. A revision of these guidelines was undertaken by CANMAT in 2008-2009 to reflect advances in the field. There is renewed interest in refined approaches to brain stimulation, particularly for treatment resistant major depressive disorder (MDD). METHODS: The CANMAT guidelines are based on a question-answer format to enhance accessibility to clinicians. An evidence-based format was used with updated systematic reviews of the literature and recommendations were graded according to Level of Evidence using pre-defined criteria. Lines of Treatment were identified based on criteria that included evidence and expert clinical support. This section on "Neurostimulation Therapies" is one of 5 guidelines articles. RESULTS: Among the four forms of neurostimulation reviewed in this section, electroconvulsive therapy (ECT) has the most extensive evidence, spanning seven decades. Repetitive transcranial magnetic (rTMS) and vagus nerve stimulation (VNS) have been approved to treat depressed adults in both Canada and the United States with a much smaller evidence base. There is also emerging evidence that deep brain stimulation (DBS) is effective for otherwise treatment resistant depression, but this is an investigational approach in 2009. LIMITATIONS: Compared to other modalities for the treatment of MDD, the data based is limited by the relatively small numbers of randomized controlled trials (RCTs) and small sample sizes. CONCLUSIONS: There is most evidence to support ECT as a first-line treatment under specific circumstances and rTMS as a second-line treatment. Evidence to support VNS is less robust and DBS remains an investigational treatment.
抑郁症以往被划分为情感性精神病、其它类型的疾病均被划分为神经 症。抑郁症是一种持久的心境低落状态,常伴有焦虑、躯体不适感和睡眠障 碍,患者有治疗要求,而无明显的运动障碍、以及幻觉、幻想、思维和行为 紊乱等精神特征,生活能力无明显影响;神经症是一組表现心情抑郁、烦恼、 紧张、恐怖、疑病、强迫症状、分离和转换症状等,除意症表现为短的发作 性症状外, 一般病程迁延可达数年或数十年,可分为恐怖性神经症、焦虑性 神经症、强迫性神经症、抑郁性神经症、癔症、疑病性神经症、神经哀弱、 其它神经症(人格解体神经症、躯体化障碍、职业性如书写痉挛)等。依据中 医理论,抑郁症、焦虑症统称为精神和心理障碍性疾病,是由于植物神经功 能紊乱而导致心境低落、焦虑、失眠多梦,幻觉、妄想、思维和行为紊乱等 精神病特征。中医认为这些症状是因情志不遂,忧思悲怒,起居不慎,饮食 不节而造成。西医治疗多采取化学药物治疗,其疗效不稳定,副作用大;而中药以其毒性小,长期服用安全,越来越多的被人们认识用于治疗精神方面 的疾病。
Brintellix通用名Vortioxetine,是一种调节和促进血清素分泌类的药物,属于非典型性抗抑郁症药物,它的机制目前还不完全清楚,但是发现它同时起到血清素再摄取抑制剂、去甲肾上腺素再摄取抑制剂、5-HT 1A受体激动剂、5-HT 1B受体部分激动剂等功能。武田制药声称,这款药物是目前唯一通过这种综合性的功能来促进血清素水平的药物,虽然每一种功能对其发挥抗抑郁作用的贡献有多大,目前为止还不是很清楚,此药除了能够改善患者的情绪外,临床研究显示还能改善认知功能,对于目前市场上销售的抗抑郁症药物来说,这可以称得上是一种具有进步性的药物。此药由武田和丹麦的灵北制药公司共同销售,在这笔交易中武田支付灵北制药4000万美元的先期付款,另外总计高达3.45亿美元的里程碑付款。2013年先后在美国和欧盟上市,预测2017年销售额8.45亿美元, 2021年销售额为17.5亿美元。
×